The anti-HER2 antibody-drug conjugate (ADC) trastuzumab emtansine, which delivers the microtubule poison mertansine (DM1) via the trastuzumab targeting antibody ligand, has not yet been administered to uterine cervix cancer patients. The gene discussed is ERBB2; the disease is cervical cancer.